Antibody cancer immunotherapy

Abstract

A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2.

1 . A method for directing an antibody to cancer cells expressing IL-13Rα2 in a subject, the method comprising the steps of:
 (a) formulating a pharmaceutical composition outside of a subject, the pharmaceutical composition comprising an antibody that specifically binds IL-13Rα2 and a pharmaceutically acceptable carrier; 
 (b) administering the pharmaceutical composition to the subject in an amount sufficient to allow the antibody to specifically bind to the cancer cells expressing IL-13Rα2 in the subject; and 
 (c) measuring stimulation of an immune response against cancer cells expressing IL-13Rα2 in the subject after administration of the pharmaceutical composition to the subject. 
 
     
     
         2 . The method of  claim 1 , wherein the antibody is a monoclonal antibody. 
     
     
         3 . The method of  claim 1 , wherein the antibody is a polyclonal antibody.